Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by SQZ Biotechnologies Company

Asset Sale and Plan of Liquidation and Dissolution Approved by SQZB Shareholders
From SQZ Biotechnologies Company
Via Business Wire
Tickers OTC SQZB
SQZ Biotechnologies Reports Third Quarter 2023 Financial Results and Recent Portfolio Updates
From SQZ Biotechnologies Company
Via Business Wire
Tickers OTC SQZB
SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting
From SQZ Biotechnologies Company
Via Business Wire
Tickers OTC SQZB
SQZ Biotechnologies Reports Second Quarter 2023 Financial Results and Recent Portfolio Updates
From SQZ Biotechnologies Company
Via Business Wire
Tickers OTC SQZB
SQZ Biotechnologies Provides Update on Collaboration with Roche
From SQZ Biotechnologies Company
Via Business Wire
Tickers OTC SQZB
SQZ Biotechnologies to Consolidate Shares with 1-for-10 Reverse Stock Split
From SQZ Biotechnologies Company
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Reports First Quarter 2023 Financial Results and Recent Portfolio Updates
From SQZ Biotechnologies Company
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Announces Confirmed Complete Response in HPV16+ Solid Tumor Patient in the Lowest-Dose Cohort of the SQZ-AAC-HPV-101 Clinical Trial
From SQZ Biotechnologies Company
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Reports Full Year 2022 Financial Results and Recent Portfolio Updates
From SQZ Biotechnologies Company
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Receives FDA Fast Track Designation for its eAPC Therapeutic Candidate for Treatment of HPV16+ Tumors and Presents Clinical Data for Multiple Programs at the European Society for Medical Oncology Immuno-Oncology Congress
From SQZ Biotechnologies Company
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ® AAC Platform’s Potential as an Effective Red Blood Cell-Derived Immunotherapy
From SQZ Biotechnologies Company
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Presents Preclinical SQZ® TIL Data Supporting Potential Ability of mRNA-Driven IL-2 and IL-12 Expression to Eliminate Need for Toxic Preconditioning and Systemic IL-2 Administration for Certain T Cell Therapies
From SQZ Biotechnologies Company
Via Business Wire
Tickers SQZ
SQZ Biotechnologies to Present at Upcoming Investor Conferences
From SQZ Biotechnologies Company
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Announces Leadership Transition
From SQZ Biotechnologies Company
Via Business Wire
Tickers SQZ
SQZ Biotechnologies and Collaborators Publish Technology Review on SQZ® APCs and Effective CD8 T Cell Activation
From SQZ Biotechnologies Company
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Presents Celiac Disease Tolerizing Antigen Carrier Preclinical Data at 2022 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting
From SQZ Biotechnologies Company
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Announces Generation of Dopaminergic Neurons from Human Pluripotent Stem Cells Through Single-Step Delivery of Six Cell-Fate Encoding RNAs
From SQZ Biotechnologies Company
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Announces Lead Cell Therapy Candidate Induced Radiographic, Symptomatic and Immune Response as Monotherapy in Post-Checkpoint HPV+ Solid Tumor Patient
From SQZ Biotechnologies Company
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Lead Cell Therapy Candidate Generated Monotherapy Clinical Response Correlated with Substantial CD8 T Cell Tumor Infiltration in HPV+ Solid Tumor at Highest Dose
From SQZ Biotechnologies Company
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Announces Acceptance by Roche Accelerator in China
From SQZ Biotechnologies Company
Via Business Wire
Tickers SQZ
SQZ Biotechnologies to Present at the Stifel 2021 Virtual Healthcare Conference
From SQZ Biotechnologies Company
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Reports Third Quarter 2021 Financial Results and Recent Portfolio Updates
From SQZ Biotechnologies Company
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Presents Regenerative Medicine Data Demonstrating Neuron Generation from Human Pluripotent Stem Cells with Single Delivery of mRNA Transcription Factor
From SQZ Biotechnologies Company
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Initial First-In-Human Data Demonstrates Investigational Cell Therapy is Safe and Can Stimulate Immune Responses in Certain Patients with Advanced or Metastatic HPV16+ Tumors
From SQZ Biotechnologies Company
Via Business Wire
Tickers SQZ
SQZ Biotech to Present at Jefferies Virtual Health Care Conference
From SQZ Biotechnologies Company
Via Business Wire
Tickers SQZ
SQZ Biotechnologies to Present First Clinical Data at the American Society of Clinical Oncology Annual Meeting from Ongoing Phase 1 Study in Patients with Advanced or Metastatic HPV+ Tumors
From SQZ Biotechnologies Company
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Reports First Quarter 2021 Financial Results and Recent Business Highlights
From SQZ Biotechnologies Company
Via Business Wire
Tickers SQZ
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.